Population pharmacokinetics of intermittent vancomycin in children with cystic fibrosis

Pharmacotherapy

Volumn 33, Issue 12, 2013, Pages 1288-1296

  Stockmann, Chris ^a,b   Sherwin, Catherine M T ^a,b   Zobell, Jeffery T ^c,d   Lubsch, Lisa ^e   Young, David C ^b,f   Olson, Jared ^a,c   Noyes, Blakeslee E ^g,h   Ampofo, Krow ^a   Spigarelli, Michael G ^a,b  

^a UNIVERSITY OF UTAH   (United States)

^b UNIVERSITY OF UTAH   (United States)

^c PRIMARY CHILDREN'S MEDICAL CENTER   (United States)

^d Intermountain Cystic Fibrosis Pediatric Center   (United States)

^e SOUTHERN ILLINOIS UNIVERSITY EDWARDSVILLE   (United States)

^f Intermountain Cystic Fibrosis Adult Center   (United States)

^g SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h SSM Cardinal Glennon Children's Medical Center   (United States)

Author keywords

MRSA; MSSA; NONMEM; pharmacometrics; Staphylococcus aureus

Indexed keywords

VANCOMYCIN;

ADOLESCENT; AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; CHILD; CYSTIC FIBROSIS; DISTRIBUTION VOLUME; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG MONITORING; DRUG SAFETY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION;

MRSA; MSSA; NONMEM; PHARMACOMETRICS; STAPHYLOCOCCUS AUREUS;

ADOLESCENT; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; BODY WEIGHT; CHILD; CYSTIC FIBROSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; FEMALE; HUMANS; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MODELS, BIOLOGICAL; NONLINEAR DYNAMICS; STAPHYLOCOCCAL INFECTIONS; TISSUE DISTRIBUTION; VANCOMYCIN;

EID: 84898896673     PISSN: 02770008     EISSN: 18759114     Source Type: Journal    
DOI: 10.1002/phar.1320     Document Type: Article

References (46)

1. The American Academy of Pediatrics. Red book, 29th ed. Report of the Committee on Infectious Diseases. Elk Grove, IL: The American Academy of Pediatrics; 2009.
2. Rybak M, Lomaestro B, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 2009; 1: 82-98.
3. Thomas S, Cantrill S, Waghorn DJ, McIntyre A,. The role of screening and antibiotic prophylaxis in the prevention of percutaneous gastrostomy site infection caused by methicillin-resistant Staphylococcus aureus. Aliment Pharmacol Ther 2007; 5: 593-7.
4. Solis A, Brown D, Hughes J, Van Saene HK, Heaf DP,. Methicillin-resistant Staphylococcus aureus in children with cystic fibrosis: an eradication protocol. Pediatr Pulmonol 2003; 3: 189-95.
5. Miall LS, McGinley NT, Brownlee KG, Conway SP,. Methicillin resistant Staphylococcus aureus (MRSA) infection in cystic fibrosis. Arch Dis Child 2001; 2: 160-2.
6. Cystic Fibrosis Foundation. Patient registry 2006 annual report. Bethesda, MD: Cystic Fibrosis Foundation; 2007.
7. Cystic Fibrosis Foundation. Patient registry 2008 annual report. Bethesda, MD: Cystic Fibrosis Foundation; 2009.
8. Dasenbrook EC, Merlo CA, Diener-West M, Lechtzin N, Boyle MP,. Persistent methicillin-resistant Staphylococcus aureus and rate of FEV1 decline in cystic fibrosis. Am J Respir Crit Care Med 2008; 8: 814-21.
9. Pleasants RA, Michalets EL, Williams DM, Samuelson WM, Rehm JR, Knowles MR,. Pharmacokinetics of vancomycin in adult cystic fibrosis patients. Antimicrob Agents Chemother 1996; 1: 186-90.
10. Boyle M, Ross T, Goldberg JD, et al. Molecular epidemiology of MRSA infection in cystic fibrosis and its clinical implications. Pediatr Pulmonol 2005; 288:Abstract 286.
11. Elizur A, Orscheln RC, Ferkol TW, et al. Panton-Valentine Leukocidin-positive methicillin-resistant Staphylococcus aureus lung infection in patients with cystic fibrosis. Chest 2007; 6: 1718-25.
12. Ren CL, Morgan WJ, Konstan MW, et al. Presence of methicillin resistant Staphylococcus aureus in respiratory cultures from cystic fibrosis patients is associated with lower lung function. Pediatr Pulmonol 2007; 6: 513-8.
13. Sawicki GS, Rasouliyan L, Pasta DJ, et al. The impact of incident methicillin resistant Staphylococcus aureus detection on pulmonary function in cystic fibrosis. Pediatr Pulmonol 2008; 11: 1117-23.
14. Dasenbrook EC, Checkley W, Merlo CA, Konstan MW, Lechtzin N, Boyle MP,. Association between respiratory tract methicillin-resistant Staphylococcus aureus and survival in cystic fibrosis. JAMA 2010; 23: 2386-92.
15. Gibson RL, Burns JL, Ramsey BW,. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med 2003; 8: 918-51.
16. Adamczyk M, Brate EM, Chiapetta EG, et al. Development of a quantitative vancomycin immunoassay for the Abbott AxSYM analyzer. Ther Drug Monit 1997; 5: 571.
17. Ludden TM, Beal SL, Sheiner LB,. Comparison of the Akaike Information Criterion, the Schwarz criterion and the F test as guides to model selection. J Pharmacokinet Biopharm 1994; 5: 431-45.
18. Karlsson KE, Grahnen A, Karlsson MO, Jonsson EN,. Randomized exposure-controlled trials; impact of randomization and analysis strategies. Br J Clin Pharmacol 2007; 3: 266-77.
19. Ette EI, Ludden TM,. Population pharmacokinetic modeling: the importance of informative graphics. Pharm Res 1995; 12: 1845-55.
20. Ette EI, Williams PJ,. Population pharmacokinetics I: background, concepts, and models. Ann Pharmacother 2004; 10: 1702-6.
21. Boxenbaum H,. Interspecies scaling, allometry, physiological time, and the ground plan of pharmacokinetics. J Pharmacokinet Biopharm 1982; 2: 201-27.
22. Ette EI,. Stability and performance of a population pharmacokinetic model. J Clin Pharmacol 1997; 6: 486-95.
23. Karlsson MO, Savic RM,. Diagnosing model diagnostics. Clin Pharmacol Ther 2007; 1: 17-20.
24. Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin- resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011; 3: e18-55.
25. Blouin RA, Bauer LA, Miller DD, Record KE, Griffen WO, Jr,. Vancomycin pharmacokinetics in normal and morbidly obese subjects. Antimicrob Agents Chemother 1982; 4: 575-80.
26. Rodvold KA, Blum RA, Fischer JH, et al. Vancomycin pharmacokinetics in patients with various degrees of renal function. Antimicrob Agents Chemother 1988; 6: 848-52.
27. Rybak MJ, Albrecht LM, Berman JR, Warbasse LH, Svensson CK,. Vancomycin pharmacokinetics in burn patients and intravenous drug abusers. Antimicrob Agents Chemother 1990; 5: 792-5.
28. Zobell JT, Young DC, Waters CD, et al. Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: I. aztreonam and carbapenems. Pediatr Pulmonol 2012; 47: 1147-58.
29. Zobell JT, Waters CD, Young DC, et al. Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: II. cephalosporins and penicillins. Pediatr Pulmonol 2012; 48: 107-22.
30. Rotschafer JC, Crossley K, Zaske DE, Mead K, Sawchuk RJ, Solem LD,. Pharmacokinetics of vancomycin: observations in 28 patients and dosage recommendations. Antimicrob Agents Chemother 1982; 3: 391-4.
31. Matzke GR, McGory RW, Halstenson CE, Keane WF,. Pharmacokinetics of vancomycin in patients with various degrees of renal function. Antimicrob Agents Chemother 1984; 4: 433-7.
32. Naqvi SH, Keenan WJ, Reichley RM, Fortune KP,. Vancomycin pharmacokinetics in small, seriously ill infants. Am J Dis Child 1986; 2: 107-10.
33. Chang D,. Influence of malignancy on the pharmacokinetics of vancomycin in infants and children. Pediatr Infect Dis J 1995; 8: 667-73.
34. Lamarre P, Lebel D, Ducharme MP,. A population pharmacokinetic model for vancomycin in pediatric patients and its predictive value in a naive population. Antimicrob Agents Chemother 2000; 2: 278-82.
35. Wrishko RE, Levine M, Khoo D, Abbott P, Hamilton D,. Vancomycin pharmacokinetics and Bayesian estimation in pediatric patients. Ther Drug Monit 2000; 5: 522-31.
36. Eiland LS, English TM, Eiland EH III,. Assessment of vancomycin dosing and subsequent serum concentrations in pediatric patients. Ann Pharmacother 2011; 5: 582-9.
37. Vance-Bryan K, Guay DR, Gilliland SS, Rodvold KA, Rotschafer JC,. Effect of obesity on vancomycin pharmacokinetic parameters as determined by using a Bayesian forecasting technique. Antimicrob Agents Chemother 1993; 3: 436-40.
38. Leader WG, Chandler MH, Castiglia M,. Pharmacokinetic optimisation of vancomycin therapy. Clin Pharmacokinet 1995; 4: 327-42.
39. Albrecht LM, Rybak MJ, Boike SC, Pancorbo S,. Comparison of serum sampling methods for determining vancomycin dosage regimens. Ther Drug Monit 1988; 1: 85-90.
40. Pryka RD, Rodvold KA, Garrison M, Rotschafer JC,. Individualizing vancomycin dosage regimens: one- versus two-compartment Bayesian models. Ther Drug Monit 1989; 4: 450-4.
41. Pou L, Rosell M, Lopez R, Pascual C,. Changes in vancomycin pharmacokinetics during treatment. Ther Drug Monit 1996; 2: 149-53.
42. DeRyke C, Alexander, DP,. Optimizing vancomycin dosing through pharmacodynamic assessment targeting area under the concentration-time curve/minimum inhibitory concentration. Hosp Pharm 2009; 9: 751-65.
43. Charles PG, Ward PB, Johnson PD, Howden BP, Grayson ML,. Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus. Clin Infect Dis 2004; 3: 448-51.
44. Kearns GL, Hilman BC, Wilson JT,. Dosing implications of altered gentamicin disposition in patients with cystic fibrosis. J Pediatr 1982; 2: 312-8.
45. Boxerbaum B, Jacobs MR, Cechner RL,. Prevalence and significance of methicillin-resistant Staphylococcus aureus in patients with cystic fibrosis. Pediatr Pulmonol 1988; 3: 159-63.
46. Kirst HA, Thompson DG, Nicas TI,. Historical yearly usage of vancomycin. Antimicrob Agents Chemother 1998; 5: 1303-4.